TW200513260A - Hepatitis C virus derived peptides - Google Patents

Hepatitis C virus derived peptides

Info

Publication number
TW200513260A
TW200513260A TW093128767A TW93128767A TW200513260A TW 200513260 A TW200513260 A TW 200513260A TW 093128767 A TW093128767 A TW 093128767A TW 93128767 A TW93128767 A TW 93128767A TW 200513260 A TW200513260 A TW 200513260A
Authority
TW
Taiwan
Prior art keywords
hepatitis
virus
derived peptides
virus derived
peptide
Prior art date
Application number
TW093128767A
Other languages
English (en)
Inventor
Kyogo Itoh
Akira Yamada
Michio Sata
Original Assignee
Univ Kurume
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kurume filed Critical Univ Kurume
Publication of TW200513260A publication Critical patent/TW200513260A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW093128767A 2003-09-22 2004-09-22 Hepatitis C virus derived peptides TW200513260A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003330258 2003-09-22

Publications (1)

Publication Number Publication Date
TW200513260A true TW200513260A (en) 2005-04-16

Family

ID=34372985

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093128767A TW200513260A (en) 2003-09-22 2004-09-22 Hepatitis C virus derived peptides

Country Status (9)

Country Link
US (1) US20080063643A1 (zh)
EP (3) EP2062590A1 (zh)
JP (2) JP4342519B2 (zh)
KR (2) KR20060087574A (zh)
CN (3) CN102659922B (zh)
CA (1) CA2539789A1 (zh)
EA (2) EA009782B1 (zh)
TW (1) TW200513260A (zh)
WO (1) WO2005028503A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4761311B2 (ja) * 2004-04-30 2011-08-31 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
JPWO2006080340A1 (ja) * 2005-01-28 2008-06-19 株式会社グリーンペプタイド Ｃ型肝炎ウイルス由来ペプチドとインターフェロンとの併用療法
JP4615567B2 (ja) * 2005-04-19 2011-01-19 株式会社グリーンペプタイド Ｃ型肝炎ウイルス感染に関連する肝疾患の予後の予測
JP2009091249A (ja) * 2006-01-23 2009-04-30 Univ Kurume Ｃ型肝炎ウイルス２ａ由来ＨＬＡ−Ａ２拘束性抗原ペプチド
JP5133706B2 (ja) 2006-01-23 2013-01-30 株式会社グリーンペプタイド Ｃ型肝炎ウイルス由来ペプチド
JPWO2007094137A1 (ja) * 2006-02-17 2009-07-02 日本電気株式会社 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
JP5031827B2 (ja) * 2006-06-01 2012-09-26 程云 予防或いは肝損傷を治療するペプチッド
WO2010050181A1 (ja) * 2008-10-27 2010-05-06 株式会社グリーンペプタイド Ｃ型肝炎ウイルスによる肝癌の発症および再発予防ワクチン
CN101696974B (zh) * 2009-09-29 2013-03-06 才新 Hla抗体特异性检测方法及细胞盘与试剂盒
FR2980362B1 (fr) 2011-09-27 2013-10-04 Sederma Sa Nouvelle utilisation cosmetique d'un extrait d'albizia julibrissin et composition topique correspondante
FR3007289B1 (fr) 2013-06-24 2015-06-19 Caster Compositions cosmetiques comprenant des extraits de plantes pour lutter contre le vieillissement cutane

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU220204B (hu) 1987-11-18 2001-11-28 Chiron Corp. HCV polipeptidek és HCV polinukleotidok, ilyen polinukleotidokat tartalmazó vektorok és ezekkel transzformált gazdasejtek, valamint HCV fertőzés kimutatására szolgáló diagnosztikumok és immunvizsgálati készlet
JP2818762B2 (ja) * 1990-01-31 1998-10-30 財団法人化学及血清療法研究所 非ａ非ｂ型肝炎ウイルス抗原ペプチドをコードする核酸断片およびその利用法
US5747339A (en) * 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
US6538126B1 (en) * 1991-06-10 2003-03-25 Lucky Limited Hepatitis C diagnostics and vaccines
WO1993011158A2 (en) * 1991-12-06 1993-06-10 Akzo Nobel N.V. Non-a, non-b peptides
ATE342730T1 (de) * 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
AU6359494A (en) * 1993-03-05 1994-09-26 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
JP3665371B2 (ja) * 1994-08-31 2005-06-29 株式会社先端生命科学研究所 Ｃ型肝炎ウイルス感染又はグループ判定のためのエピトープキメラ抗原ペプチド、その製法、及びそれを使用する感染又はグループ判定法
ATE482974T1 (de) * 1997-11-06 2010-10-15 Innogenetics Nv Multimere peptide, die auf dem hepatitis c virus hüllprotein basieren, für diagnostische verwendung und für impfzwecke
CA2323632A1 (en) * 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
EP0947525A1 (en) * 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
CA2685270C (en) * 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same
AU6226100A (en) * 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
ES2373642T3 (es) * 2000-05-23 2012-02-07 Washington University Variantes de vhc.
ATE303597T1 (de) * 2000-07-07 2005-09-15 Medmira Inc Hcv mosaik antigen zusammensetzung
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
WO2002083124A1 (en) * 2000-10-06 2002-10-24 Probiochem, Llc A composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2002055548A2 (en) * 2001-01-11 2002-07-18 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
EP1357127A1 (de) * 2002-04-10 2003-10-29 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
JP2003330258A (ja) 2002-05-13 2003-11-19 Sharp Corp 画像形成装置
CA2566506A1 (en) * 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
JP5133706B2 (ja) * 2006-01-23 2013-01-30 株式会社グリーンペプタイド Ｃ型肝炎ウイルス由来ペプチド

Also Published As

Publication number Publication date
EP1676856A4 (en) 2008-03-05
CN1856503A (zh) 2006-11-01
KR20070050993A (ko) 2007-05-16
EP1676856A1 (en) 2006-07-05
CA2539789A1 (en) 2005-03-31
CN101230096A (zh) 2008-07-30
WO2005028503A1 (ja) 2005-03-31
EA200600639A1 (ru) 2006-08-25
JP2009034102A (ja) 2009-02-19
EP2267004A3 (en) 2011-04-27
CN102659922A (zh) 2012-09-12
JPWO2005028503A1 (ja) 2007-11-15
EA009782B1 (ru) 2008-04-28
KR100818578B1 (ko) 2008-04-02
EA200701870A1 (ru) 2008-02-28
EP2062590A1 (en) 2009-05-27
JP4342519B2 (ja) 2009-10-14
KR20060087574A (ko) 2006-08-02
CN101230096B (zh) 2012-07-04
EP2267004A2 (en) 2010-12-29
US20080063643A1 (en) 2008-03-13
JP4342597B2 (ja) 2009-10-14
CN102659922B (zh) 2013-11-06

Similar Documents

Publication Publication Date Title
DE69518642D1 (de) Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c
UA85536C2 (en) Viral antigens
DE69232906D1 (de) Detektion des Hepatis-C Virus.
TW200513260A (en) Hepatitis C virus derived peptides
NO20044897L (no) Hepatitt C virus inhibitorer
ATE423127T1 (de) Peptidinhibitoren der ns3-protease des hepatoitis c virus
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
WO2009014216A1 (ja) Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
HU9503219D0 (en) Methods of typing hepatitis c virus and reagents for use therein
HUP0101719A2 (hu) Javított immundiagnosztikai vizsgálati eljárások redukáló ágensek alkalmazásával
AU2001272257A1 (en) Hcv mosaic antigen composition
ATE370160T1 (de) Peptide mit affinität zu gp120, und ihre verwendungen
DK1002092T3 (da) Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf
EP1878797A3 (en) Antigenic peptides for grouping hepatitis c virus, kit comprising the same and methods for its grouping using the same
ATE240349T1 (de) Peptide zur inhibierung von hpv e6-proteinen
TW200720656A (en) Prediction of prognosis of liver disease associated with hepatitis c virus infection
ATE305522T1 (de) Nachweis von humanen papillomviren
DE69106141T2 (de) Non-a non-b sequenzen.
ATE359293T1 (de) Von vca-p18 kapsidantigen des epstein-barr-virus abgeleitete peptide und ihre verwendung
ATE482974T1 (de) Multimere peptide, die auf dem hepatitis c virus hüllprotein basieren, für diagnostische verwendung und für impfzwecke
ATE391721T1 (de) Modifizierte hiv-1-peptide und ihre verwendung beim nachweisen von anti-hiv-antikörpern
DE69824001D1 (de) Reagenz zum nachweis und weiterverfolgen von virusinfektionen
HUP0302416A2 (hu) Tisztított hepatitis-C vírusmembrán-proteinek diagnosztikai és terápiás célú alkalmazása
ATE426038T1 (de) Nachweis des rinderdiarrhoevirus in haarproben